Back to results
US 9,808,500 B2Granted
Antithrombotic nanoparticle
AssigneeWashington University
InventorsSamuel A. Wickline, Jacob Myerson, Rohun Palekar, Hua Pan
Life of this patent
Estimating the term…
Abstract
The present invention encompasses an antithrombotic nanoparticle and use thereof.
Claims12
A method of inhibiting thrombin activation of a protein-activated receptor (PAR) in a subject, the method comprising administering to the subject an antithrombotic nanoparticle comprising a core and an outer layer,
- wherein the core of the antithrombotic nanoparticle comprises a perfluorocarbon that is a liquid at about 37° C. and the outer layer comprises a mixture of a lipid and a surfactant;
- wherein the exterior of the antithrombotic nanoparticle comprises a direct thrombin inhibitor covalently conjugated to the exterior via the lipid component of the nanoparticle's outer layer, such that the antithrombotic nanoparticle has a second order kinetic constant for the direct thrombin inhibitor-thrombin interaction that is greater than the same kinetic constant of the direct thrombin inhibitor by itself;
- and
- wherein the antithrombotic nanoparticle is antithrombotic but does not substantially alter the clotting time of a subject's blood plasma.
1 more element
A method of inhibiting thrombin activation of a protein-activated receptor (PAR) in an organ, the method comprising contacting the organ with an antithrombotic nanoparticle comprising a core and an outer layer,
- wherein the core of the antithrombotic nanoparticle comprises a perfluorocarbon that is a liquid at about 37° C. and the outer layer comprises a mixture of a lipid and a surfactant;
- wherein the exterior of the antithrombotic nanoparticle comprises a direct thrombin inhibitor covalently conjugated to the exterior via the lipid component of the nanoparticle's outer layer, such that the antithrombotic nanoparticle has a second order kinetic constant for the direct thrombin inhibitor-thrombin interaction that is greater than the same kinetic constant of the direct thrombin inhibitor by itself;
- and
- wherein the antithrombotic nanoparticle is antithrombotic but does not substantially alter the clotting time of a subject's blood plasma.
1 more element
Dependencies are inferred from the claim text.